专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010049489A1 METHOD FOR FAST DETECTION AND IDENTIFICATION OF MICRO-ORGANISMS 审中-公开
标题翻译：用于快速检测和鉴定微生物的方法
公开(公告)号：WO2010049489A1
公开(公告)日：2010-05-06
申请号：PCT/EP2009/064292
申请日：2009-10-29
申请人： CHECK-POINTS HOLDING B.V. , VOS, Pieter , THIJSSEN, Joost , DE LEVITA, Wouter
发明人： VOS, Pieter , THIJSSEN, Joost , DE LEVITA, Wouter
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6862 , C12Q2565/1015 , C12Q2563/179 , C12Q2537/149 , C12Q2561/113
摘要： The present invention relates to a specific method accomplishing fast and specific detection, identification and characterization of contaminating micro-organisms in various samples. A method has been developed based on the detection of species-specific and/or strain-specific nucleotide sequences that are uniquely identified and amplified and subsequently detected on a microarray using addressable identifier ZIP oligonucleotides. By using a two step screening process, the method of the present invention enables in first instance the fast screening of a multitude of samples for the presence or the absence of specific micro- organisms in such samples, while in a second screening step the positive results of the first step are further processed to identify and characterize the detected micro-organisms.
摘要翻译：本发明涉及实现各种样品中污染微生物的快速和特异性检测，鉴定和表征的具体方法。已经开发了基于特异性鉴定和/或菌株特异性核苷酸序列的检测的方法，所述核苷酸序列被唯一鉴定和扩增，并且随后在微阵列上使用可寻址标识符ZIP寡核苷酸检测。通过使用两步筛选方法，本发明的方法首先能够快速筛选这些样品中存在或不存在特定微生物的大量样品，而在第二筛选步骤中，阳性结果进一步处理第一步以识别和表征检测到的微生物。

2. 发明申请

WO2009121959A1 USE OF GLYCOSAMINOGLYCAN FOR RESTORING GLYCOCALYX 审中-公开
标题翻译：使用谷氨酰胺凝胶来恢复甘氨酸
公开(公告)号：WO2009121959A1
公开(公告)日：2009-10-08
申请号：PCT/EP2009/054020
申请日：2009-04-03
申请人： UNIVERSITEIT MAASTRICHT , VINK, Hans , STROES, Erik Sjoerd Gerard
发明人： VINK, Hans , STROES, Erik Sjoerd Gerard
IPC分类号： A61K31/726 , A61K31/727 , A61K31/737 , A61P3/10 , A61P25/02 , A61P13/12 , A61P27/02
CPC分类号： A61K31/726 , A61K31/727 , A61K31/737
摘要： The invention is directed to the use of glycosaminoglycans for restoring glycocalyx functions or preventing glycocalyx damage. The effectiveness of glycosaminoglycans is directed in all pathologies where glycocalyx damage or this function may be etiologically cause of many pathologies such as: vascular disease, septic states, atherosclerosis syndrome, inflammation states and disease related to ischemia, peritoneal impairment, myocardial infarction, cerebrum- vascular events, alteration of enzymatic glycosylation in diabetes, kidney injury, intestinal disease as ulcerous colitis conditions, pneumoconiosis involving alteration of metabolic activity of pulmonary endothelium.
摘要翻译：本发明涉及糖胺聚糖用于恢复糖萼功能或防止糖萼损伤的用途。糖胺聚糖的有效性针对所有病理学，其中糖萼损伤或这种功能可能是病因引起的许多病理学，例如：血管疾病，脓毒症状态，动脉粥样硬化综合征，炎症状态和与缺血相关的疾病，腹膜损伤，心肌梗塞，血管事件，糖尿病酶糖基化的改变，肾损伤，肠道疾病作为溃疡性结肠炎病症，涉及改变肺内皮代谢活性的肺尘埃沉着病。

3. 发明申请

WO2011083059A1 BACTERIAL MUTANTS AND USES THEREOF IN PROTEIN PRODUCTION 审中-公开
标题翻译：细菌菌株及其在蛋白质生产中的应用
公开(公告)号：WO2011083059A1
公开(公告)日：2011-07-14
申请号：PCT/EP2010/070683
申请日：2010-12-23
申请人： UNIVERSITEIT GENT , BEAUPREZ, Joeri
发明人： BEAUPREZ, Joeri
IPC分类号： C07K14/245 , C12N15/70 , C12P21/02
CPC分类号： C12N15/70 , C12P21/02
摘要： The present invention relates to a method for obtaining increased product yields and/or for eliminating by-product formation in micro-organisms, and to mutants and/or transformants for use in said methods. More particularly, it relates to bacterial mutants and/or transformants that are affected in the primary metabolism for enhanced product formation, for enhanced product yield and/or for eliminating production of by-products, especially mutants and/or transformants that are affected in the repression of the glyoxylate bypass and in the chromosomal gene expression in response to deprivation of oxygen or in response to absence/presence of carbon compounds such as glycerol, fatty acids, glyoxylate, acetate and the like.
摘要翻译：本发明涉及一种用于获得增加的产物产率和/或消除微生物中副产物形成的方法，以及用于所述方法的突变体和/或转化体。更具体地说，它涉及在初级代谢中受影响以增强产物形成，提高产物产量和/或用于消除副产物，特别是受影响的突变体和/或转化体的产生的细菌突变体和/或转化体。乙醛酸酯旁路的抑制和染色体基因表达响应于剥夺氧或响应于碳化合物如甘油，脂肪酸，乙醛酸盐，乙酸盐等的存在/存在。

4. 发明申请

WO2009068685A1 DIAGNOSTIC AND THERAPEUTIC TOOLS FOR DISEASES ALTERING VASCULAR FUNCTION 审中-公开
标题翻译：用于改变血管功能的疾病的诊断和治疗工具
公开(公告)号：WO2009068685A1
公开(公告)日：2009-06-04
申请号：PCT/EP2008/066524
申请日：2008-12-01
申请人： UNIVERSITEIT MAASTRICHT , ACADEMISCH ZIEKENHUIS MAASTRICHT , VINK, Hans , STROES, Erik Sjoerd Gerard
发明人： VINK, Hans , STROES, Erik Sjoerd Gerard
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/525 , G01N2400/50 , G01N2800/32 , G01N2800/323 , G01N2800/328
摘要： The invention relates to diagnostic and therapeutic tools and applications, particularly useful in diseases that affect vascular health and in inflammatory diseases. In particular, said diagnostic and therapeutic tools employ suitable detection or modulation of endothelial glycocalyx.
摘要翻译：本发明涉及诊断和治疗工具和应用，特别适用于影响血管健康和炎性疾病的疾病。特别地，所述诊断和治疗工具使用合适的内皮糖萼的检测或调节。

5. 发明申请

WO2008090223A2 TREATMENT OF IMMUNE DISEASE BY MUCOSAL DELIVERY OF ANTIGENS 审中-公开
标题翻译：通过胶原蛋白交付抗原治疗免疫疾病
公开(公告)号：WO2008090223A2
公开(公告)日：2008-07-31
申请号：PCT/EP2008/050900
申请日：2008-01-25
申请人： ACTOGENIX N.V. , ROTTIERS, Pieter , SNOECK, Veerle
发明人： ROTTIERS, Pieter , SNOECK, Veerle
IPC分类号： A61K39/35 , C12R1/225
CPC分类号： A61K39/00 , A61K39/0008 , A61K39/001 , A61K39/35 , A61K39/36 , A61K2039/523 , A61K2039/542 , A61K2039/55566 , C12R1/225
摘要： The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery bymicro-organism, in particularLactococcus lactis,of secreted immunodominant antigens.
摘要翻译：本发明涉及通过分泌性免疫显性抗原的微生物特别是乳酸乳球菌的粘膜递送来治疗自身免疫性和过敏性疾病。

6. 发明申请

WO2008071751A1 DELIVERY OF BINDING MOLECULES TO INDUCE IMMUNOMODULATION 审中-公开
标题翻译：交付结合分子诱导免疫调节
公开(公告)号：WO2008071751A1
公开(公告)日：2008-06-19
申请号：PCT/EP2007/063851
申请日：2007-12-12
申请人： ACTOGENIX N.V. , DE CREUS, An , ROTTIERS, Pieter
发明人： DE CREUS, An , ROTTIERS, Pieter
IPC分类号： C07K16/24 , C12N15/74 , A61P1/00 , C12N15/81 , A61K35/74 , A61K36/06 , A61K36/064 , C12N1/16
CPC分类号： C07K16/244 , A61K35/747 , A61K38/1793 , A61K38/19 , A61K38/191 , A61K2039/505 , C07K16/00 , C07K16/241 , C07K2317/10 , C07K2317/569
摘要： The present invention relates to the delivery of binding molecules, such as antibodies, antibody fragments, single antibody variable domains, soluble receptors, ligands and dominant negative variants, to induce an immunomodulation in a patient. More specifically, the invention relates to the production of a medicament comprising said binding molecules producing micro-organisms, and the use of this medicament in the treatment of immune mediated diseases.
摘要翻译：本发明涉及结合分子如抗体，抗体片段，单抗体可变结构域，可溶性受体，配体和显性失活变体的递送，以诱导患者的免疫调节。更具体地，本发明涉及包含产生微生物的所述结合分子的药物的生产，以及该药物用于治疗免疫介导的疾病的用途。

7. 发明申请

WO2007039255A1 TUMOR ANGIOGENESIS ASSOCIATED GENES AND A METHOD FOR THEIR IDENTIFICATION 审中-公开
标题翻译：肿瘤血管发生相关基因及其鉴定方法
公开(公告)号：WO2007039255A1
公开(公告)日：2007-04-12
申请号：PCT/EP2006/009496
申请日：2006-09-29
申请人： UNIVERSITEIT MAASTRICHT , GRIFFIOEN, Arjan, Willem , VAN BEIJNUM, Judith, Rosina
发明人： GRIFFIOEN, Arjan, Willem , VAN BEIJNUM, Judith, Rosina
IPC分类号： C07K14/82 , C12Q1/68 , C12N15/10
CPC分类号： C07K14/82 , C12Q1/6886 , C12Q2600/136
摘要： Crucial to designing anti-angiogenic and vascular targeting approaches is the identification of specific target molecules. We compared transcriptional profiles of tumor endothelial cells with that of normal resting endothelial cells, normal but angiogenically activated placental endothelial cells, and cultured endothelial cells. Although the majority of transcripts were classified as general angiogenesis markers, we identified 17 genes that show specific overexpression in tumor endothelium. Antibody targeting of four cell-surface expressed or secreted products (vimentin, CD59, HMGB1 and IGFBP7) inhibited angiogenesis in vitro and in vivo. Finally, targeting endothelial vimentin in a mouse tumor model significantly inhibited tumor growth and reduced microvessel density. Our results demonstrate the utility of the identification and subsequent targeting of specific tumor endothelial markers for anticancer therapy.
摘要翻译：设计抗血管生成和血管靶向方法的关键是确定特异性靶分子。我们将肿瘤内皮细胞的转录谱与正常的静止内皮细胞，正常但血管生成活化的胎盘内皮细胞和培养的内皮细胞进行比较。虽然大多数转录物被归类为一般的血管发生标记，我们确定了17个在肿瘤内皮中表现出特异性过度表达的基因。四种细胞表面表达或分泌产物（波形蛋白，CD59，HMGB1和IGFBP7）的抗体靶向在体外和体内抑制血管生成。最后，靶向小鼠肿瘤模型中的内皮波形蛋白显着抑制肿瘤生长和降低微血管密度。我们的研究结果证明了用于抗癌治疗的特异性肿瘤内皮标志物的鉴定和随后靶向的实用性。

8. 发明申请

WO2006125513A1 GENETIC ASSOCIATION OF POLYMORPHISMS IN THE ATF6-ALPHA GENE WITH INSULIN RESISTANCE PHENOTYPES 审中-公开
标题翻译： ATF6-ALPHA基因中具有胰岛素抵抗性的多态性遗传协会
公开(公告)号：WO2006125513A1
公开(公告)日：2006-11-30
申请号：PCT/EP2006/004216
申请日：2006-05-05
申请人： UNIVERSITEIT MAASTRICHT , MEEX, Steven J.R. , VAN DER KALLEN, Carla J.H. , DE BRUIN, Tjerk W.A. , VAN GREEVENBROEK, Marleen M.J. , VLIETINCK, Robert , AYOUBI, Torik A.Y.
发明人： MEEX, Steven J.R. , VAN DER KALLEN, Carla J.H. , DE BRUIN, Tjerk W.A. , VAN GREEVENBROEK, Marleen M.J. , VLIETINCK, Robert , AYOUBI, Torik A.Y.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/158
摘要： The present invention relates to polymorphisms in the ATF6-alpha gene or locus which show genetic association with insulin resistance phenotypes, such as metabolic syndrome and type 2 diabetes. The present invention further relates to methods of genetic diagnosis of insulin resistance phenotypes comprising testing polymorphisms in the ATF6-alpha gene or locus and to reagents suitable for use in such methods. Further the invention relates to screening methods for compounds modulating the expression and/or function of ATF6-alpha gene and/or protein, which are useful in treatment and/or prevention of insulin resistance phenotypes.
摘要翻译：本发明涉及与胰岛素抵抗表型遗传关联的ATF6-α基因或基因座中的多态性，如代谢综合征和2型糖尿病。本发明还涉及胰岛素抵抗表型的遗传诊断方法，其包括测试ATF6-α基因或基因座中的多态性以及适用于这些方法的试剂。此外，本发明涉及调节ATF6-α基因和/或蛋白质的表达和/或功能的化合物的筛选方法，其可用于治疗和/或预防胰岛素抗性表型。

9. 发明申请

WO2007080129A1 TREATMENT AND DIAGNOSIS OF ABNORMAL BONE DENSITY WITH AN INHIBITOR OF THE GLYPICAN-SCLEROSTIN INTERACTION 审中-公开
标题翻译：治疗和诊断异常骨质疏松与糖尿病相关的抑制剂
公开(公告)号：WO2007080129A1
公开(公告)日：2007-07-19
申请号：PCT/EP2007/000295
申请日：2007-01-15
申请人： A CHAN HOLDING B.V. , CHAN, Alan, Barry
发明人： CHAN, Alan, Barry
IPC分类号： C07K16/28 , C07K16/18 , A61K38/18 , A61K39/395 , G01N33/15
CPC分类号： C07K16/28 , C07K16/18 , G01N33/6893 , G01N2333/51 , G01N2440/38 , G01N2500/02 , G01N2800/105
摘要： The present invention is based on the finding that in order for sclerostin to achieve its inhibitory effect, i.e., for sclerostin to inhibit bone deposition, it must be bound to glypican. The present invention provides a composition and methods of treatment for abnormal bone density. It also provides methods of identifying agent for said treatments, and methods of diagnosis.
摘要翻译：本发明基于以下发现：为了使硬皮蛋白达到其抑制作用，即对于硬皮蛋白抑制骨沉积，必须将其与磷脂酰胆碱相结合。本发明提供了治疗异常骨密度的组合物和方法。它还提供了用于鉴定所述治疗的药剂的方法和诊断方法。

10. 发明申请

WO2011029946A1 A PROTEOLYTIC PRODUCT OF HISTONE H2A AS A MARKER FOR CANCER 审中-公开
标题翻译：作为癌症标记物的HISTONE H2A的抗坏血酸产品
公开(公告)号：WO2011029946A1
公开(公告)日：2011-03-17
申请号：PCT/EP2010/063425
申请日：2010-09-14
申请人： Universiteit Gent , DHAENENS, Maarten , DEFORCE, Dieter
发明人： DHAENENS, Maarten , DEFORCE, Dieter
IPC分类号： C07K7/08 , G01N33/68
CPC分类号： C07K14/47 , G01N33/57426 , G01N33/57484
摘要： The present invention relates to proteolytic products of histone H2A. In particular, the present invention discloses a peptide having the amino acid sequence VTIAQGGVLPNIQAV which can be used to determine cleavage of histone H2A. More in particular, the present invention relates to the latter peptide as a marker to diagnose or to determine prognosis of cancer such as chronic lymphocytic leukemia.
摘要翻译：本发明涉及组蛋白H2A的蛋白水解产物。特别地，本发明公开了具有氨基酸序列VTIAQGGVLPNIQAV的肽，其可用于确定组蛋白H2A的切割。更具体地，本发明涉及后一种肽作为诊断或确定诸如慢性淋巴细胞性白血病的癌症预后的标志物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式